Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial

Affiliations

• ¹ Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital; Department of Infectious Disease, Peking University International Hospital, Beijing, China.
• ² Hebei Petro China Central Hospital, Langfang, China.
• ³ State Key Laboratory of Infectious, Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
• ⁴ National Institutes for Food and Drug Control, Beijing, China.
• ⁵ Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China.
• ⁶ Department of Pharmacy, Peking University First Hospital; Institute of Clinical Pharmacology, Peking University Beijing, China. Electronic address: cui.pharm@pkufh.com.
• ⁷ Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China; Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: LX@sinocelltech.com.